Applied BioCode announced the retirement of Chris Bernard as Chief Executive Officer. Chris Bernard has served as CEO for the past two years and has been instrumental in guiding the company through a period of growth and innovation. During his tenure, Chris played a pivotal role in advancing Applied BioCode’s strategic initiatives and driving the company’s commitment to delivering cutting-edge solutions to the molecular diagnostics market. His leadership and dedication have been invaluable in positioning Applied BioCode as a leader in multiplex testing technologies.
Following his retirement, Winston Ho, Ph.D., Founder and President, will step into the role of Chief Executive Officer until a new CEO is appointed. “I am honored to once again have the opportunity to lead Applied BioCode as we continue our mission to revolutionize multiplex testing and improve healthcare outcomes,” said Dr. Winston Ho. “I want to extend my heartfelt thanks to Chris for his leadership and dedication to the company. I am committed to building upon the strong foundation we have laid.”
Applied BioCode remains steadfast in its commitment to delivering innovative solutions that empower researchers, clinicians, and healthcare providers to make more informed decisions and enhance patient care.
Source: Applied BioCode
